Alnylam Launches “Alnylam P5x25” Strategy For Planned Transition To A Top Five Biotech In Market Capitalization Over Next Five Years

Further, at Dec. 31, 2020, Alnylam had preliminary cash, cash equivalents, and marketable securities of approximately $1.9 billion, as compared to $1.5 billion at Dec. 31, 2019. The company balance sheet was strengthened by the 2020 strategic financing collaboration with Blackstone (BK).

“We are extremely pleased with ONPATTRO and GIVLAARI performance in the fourth quarter and cumulatively for the year, reflecting strong commercial execution, a substantial increase in demand and new patient adds, despite the ongoing COVID-19 pandemic.

"Additionally, we’re pleased to report that strong top-line revenue growth at the upper end of our guidance range and disciplined R&D and SG&A investments have delivered on a lower non-GAAP operating loss for 2020 compared with the prior year.

"We believe we’re now firmly on our way toward a self-sustainable financial profile with significant growth from four revenue generating assets and moderated operating expenses, and a balance sheet that supports achievement of profitability without the need to access the equity markets,” said Jeff Poulton, Chief Financial Officer of Alnylam.

“As we now launch our Alnylam P5x25 strategy, we’re committed to delivering consistently strong financial performance driven by 40% or greater revenue CAGR over the next five years with non-GAAP profitability achieved within the period.”

Alnylam management will discuss these preliminary selected financial results and commercial updates during a webcast presentation at the 39th Annual J.P. Morgan (JPM) Healthcare Conference tomorrow, Monday, Jan. 11, 2021, at 8:20 A.M. ET.

About Alnylam Pharmaceuticals

Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases.

View single page >> |

* The preliminary selected financial results are unaudited, subject to adjustment, and provided as an approximation in advance of the company’s announcement of complete financial results in ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.